Rapid7, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Rapid7, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $685.08M | Feb 24, 2023 |
| FY2022 | Dec 31, 2021 | $535.40M | Feb 24, 2023 |
| FY2022 | Dec 31, 2020 | $411.49M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $326.95M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $244.09M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $200.94M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $157.44M | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $110.53M | Mar 8, 2018 |
| FY2016 | Dec 31, 2014 | $76.88M | Mar 9, 2017 |
| FY2015 | Dec 31, 2013 | $60.03M | Mar 10, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $859.79M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $844.01M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $777.71M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $685.08M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $535.40M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $411.49M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $326.95M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $244.09M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $200.94M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $157.44M | Feb 28, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $110.53M | Mar 10, 2016 |
| FY2015 | Dec 31, 2014 | $76.88M | Mar 10, 2016 |
| FY2015 | Dec 31, 2013 | $60.03M | Mar 10, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $604.75M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $592.97M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $545.66M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $470.73M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $366.46M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $289.97M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $235.80M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $173.01M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $144.03M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $117.71M | Feb 28, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.38M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $25.53M | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | $15.41M | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | $6.54M | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | $1.41M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $19.12M | Feb 19, 2026 |
| FY2025 | Sep 30, 2023 | ($77.21M) | Feb 19, 2026 |
| FY2025 | Jun 30, 2023 | ($68.18M) | Feb 19, 2026 |
| FY2025 | Mar 31, 2023 | ($26.54M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($124.72M) | Feb 28, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.57M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $35.04M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($84.29M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($111.61M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($120.07M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($74.10M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | ($46.00M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($53.04M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($48.79M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($49.05M) | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $190.66M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $173.13M | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | $44.98M | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | $40.45M | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | $41.37M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $40.03M | Feb 19, 2026 |
| FY2025 | Sep 30, 2023 | $40.25M | Feb 19, 2026 |
| FY2025 | Jun 30, 2023 | $51.16M | Feb 19, 2026 |
| FY2025 | Mar 31, 2023 | $46.49M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $189.97M | Feb 28, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $153.83M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $171.67M | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | $107.90M | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | $63.93M | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | $31.07M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $104.28M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $78.20M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $53.92M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $4.89M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | ($1.42M) | Feb 24, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.60M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.43M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $4.37M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $20.38M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $9.01M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $13.80M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $29.43M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $12.81M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $4.82M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $4.50M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.73B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.65B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.51B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.36B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $1.30B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $913.12M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $664.91M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $559.37M | Feb 28, 2020 |
| FY2018 | Jan 1, 2018 | $311.33M | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $284.14M | Feb 28, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.57B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.63B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.62B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.48B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $1.42B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $841.59M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $581.75M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $472.05M | Feb 28, 2020 |
| FY2018 | Jan 1, 2018 | $261.31M | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $259.98M | Feb 28, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.73M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $17.71M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($118.18M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | ($120.07M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | ($126.00M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $71.54M | Feb 26, 2024 |
| FY2022 | Dec 31, 2019 | $83.17M | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | $87.32M | Feb 24, 2022 |
| FY2018 | Jan 1, 2018 | $50.03M | Feb 28, 2019 |
| FY2020 | Dec 31, 2017 | $24.15M | Feb 26, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $575.27M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $575.27M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $536.35M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $515.63M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $515.26M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $213.60M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $97.87M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $88.42M | Feb 26, 2021 |
| FY2018 | Jan 1, 2018 | $83.16M | Feb 28, 2019 |
| FY2019 | Dec 31, 2017 | $83.16M | Feb 28, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($964.65M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($988.03M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($1.01B) | Feb 19, 2026 |
| FY2023 | Dec 31, 2022 | ($860.75M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($736.03M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($617.28M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($518.43M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($464.59M) | Feb 28, 2020 |
| FY2018 | Jan 1, 2018 | ($409.04M) | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | ($434.91M) | Feb 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $246.66M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $334.69M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $213.63M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $207.29M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $164.58M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $173.62M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $123.41M | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | $99.57M | Feb 28, 2020 |
| FY2018 | Jan 1, 2018 | $51.56M | Feb 28, 2019 |
| FY2019 | Dec 31, 2017 | $51.56M | Feb 28, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2014 | $16.87M | Mar 10, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2025 | Sep 30, 2023 | (1) | Feb 19, 2026 |
| FY2025 | Jun 30, 2023 | (1) | Feb 19, 2026 |
| FY2025 | Mar 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 28, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2025 | Sep 30, 2023 | (1) | Feb 19, 2026 |
| FY2025 | Jun 30, 2023 | (1) | Feb 19, 2026 |
| FY2025 | Mar 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 28, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 65.85M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 63.50M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 61.71M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 59.72M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 57.70M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 52.23M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 49.91M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 47.60M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 44.05M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 42.55M | Mar 8, 2018 |